All In Biotech

Drug Trial Radar · NCT05315258

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma With Molecular Relapsed Disease

Last checked: Nov 20, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

850

Planned (sponsor's estimate)

Start

Jul 25, 2022

Primary completion

Dec 30, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Immunocore Ltd
First posted
Apr 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma. This research study is investigating using a new blood test to decide when to give a drug called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help patients with cutaneous or uveal melanoma live longer.

Conditions

  • Melanoma (Skin)
  • Melanoma, Uveal

Interventions

  • TebentafuspDrug

    Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimate the rate of molecular response (MR) to tebentafusp in each of 2 cohorts A. Cutaneous melanoma with MRD B. Uveal melanoma with MRDTime frame: ctDNA taken at baseline until end of treatment (maximum of 6 months)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Cambridge University Hospitals NHS Foundation Trust (Screening only)

    Cambridge, United Kingdom

  • The Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • The Clatterbridge Cancer Centre

    Liverpool, United Kingdom

  • University College London Hospital

    London, United Kingdom

  • The Christie Hospital

    Manchester, United Kingdom

  • Mount Vernon Cancer Centre

    Middlesex, United Kingdom

  • Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle, United Kingdom

  • Churchill Hospital, Oxford University Hospitals NHS Trust

    Oxford, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust (Screening only)

    Sheffield, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.